Optometric Clinical Practice
Volume 2

Issue 1

2020

A Vision- and Life-threatening Case of Peripheral Ulcerative
Keratitis
Len V. Koh OD
Mann-Grandstaff VAMC, len.koh@va.gov

Megan E. McChesney MD
Mann-Grandstaff VAMC, megan.mcchesney@va.gov

Chad E. Gosnell OD
Mann-Grandstaff VAMC, chad.gosnell2@va.gov

Ryan N. Ngo OD
Mann-Grandstaff VAMC, ryan.ngo5@va.gov

Follow this and additional works at: https://athenaeum.uiw.edu/optometric_clinical_practice
Part of the Optometry Commons
The Athenaeum provides a publication platform for fully open access journals, which means that all
articles are available on the Internet to all users immediately upon publication. However, the opinions and
sentiments expressed by the authors of articles published in our journal does not necessarily indicate the
endorsement or reflect the views of the University of the Incarnate Word and its employees. The authors
are solely responsible for the content of their work. Please address questions to athenaeum@uiwtx.edu.

Recommended Citation
Koh LV, McChesney ME, Gosnell CE, Ngo RN. A Vision- and Life-threatening Case of Peripheral Ulcerative
Keratitis. Optometric Clinical Practice. 2020; 2(1). doi: 10.37685/uiwlibraries.2575-7717.2.1.1016.
https://doi.org/10.37685/uiwlibraries.2575-7717.2.1.1016

This Case Report is brought to you for free and open access by The Athenaeum. It has been accepted for inclusion
in Optometric Clinical Practice by an authorized editor of The Athenaeum. For more information, please contact
athenaeum@uiwtx.edu.

A Vision- and Life-threatening Case of Peripheral Ulcerative Keratitis
Abstract
Background: Peripheral ulcerative keratitis (PUK) is a rare but severe ocular manifestation most
commonly associated with rheumatoid arthritis amongst other autoimmune diseases. Quick diagnosis
and co-management with corneal specialist and rheumatologist are crucial to preserve vision and life. A
rare case of PUK associated with rheumatoid arthritis (RA) is presented with updates on current
understanding and co-management of this condition.
Case Report: A 76 year-old Caucasian male presented to the eye clinic on a Friday as a new patient, with a
chief complaint of a red right eye started two weeks ago and was treated with erythromycin ointment, but
it got worse with moderate pain so he was referred over from the urgent care clinic. His BCVA OD, OS was
20/80 PHNI and PH20/25, respectively. Anterior segment evaluation showed severe conjunctival
chemosis and injection, a superior temporal circular infiltrate and an inferior temporal linear infiltrate
across the cornea with moderate corneal edema. Chart review confirmed the patient has been treated for
rheumatoid arthritis with hydroxychloroquine and leflunomide for several years. The patient was
diagnosed with PUK with mild scleritis associated with (RA) and initially treated with tobradex topical
drops OD qid. His rheumatologist was contacted for co-management, and the patient was to return to
clinic after the weekend. On the follow up visit, the patient felt better but the linear infiltrate persisted so
oral prednisone 60mg/day was started with ofloxacin qid instead of Tobradex qid. The condition
continued to improve over the next few follow up however the linear thinning of the cornea was not fully
resolved so the patient was referred to a local corneal specialist. His rheumatologist continued to
manage his RA closely and the patient confirmed that he was doing better overall at the latest visit.
Conclusion: In cases of PUK with stromal thinning and scleritis, autoimmune diseases such as RA and
systemic lupus erythema often are the underlying systemic cause. Prompt diagnosis and co-management
with other specialists are essential to minimize irreversible vision loss and save lives.
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INTRODUCTION

Peripheral ulcerative keratitis (PUK) is a rare and severe ocular manifestation
associated with autoimmune diseases that leads to peripheral corneal thinning and
potential corneal perforation. PUK has been reported in patients with rheumatoid
arthritis (RA), polyarteritis nodosa, inflammatory bowel disease, collagen vascular
diseases such as systemic lupus erythematosus (SLE) and granulomatosis with
polyangiitis (GPA) (Table 1).1
Systemic autoimmune vasculitic
disease

Dermatological disorders
Inflammatory bowel disease
Local ocular immunity

Rheumatoid arthritis
Wegener granulomatosis/
granulomatosis with polyangiitis
Systemic lupus erythematosus
Polyarteritis nodosa
Sjogren Syndrome
Acne rosacea
Cicatricial pemphigoid
Stevens-Johnson syndrom
Crohn disease
Mooren ucer

Table 1: Major Autoimmune Diseases Causing Peripheral Ulcerative Keratitis

The most prevalent forms of autoimmune diseases are RA and SLE. PUK is most
commonly associated with RA, followed by GPA. The pathophysiology of
autoimmune diseases remains to be fully uncovered. This group of diseases affect
most of the organs in the body. The eye, a specialized sensory organ, can be affected
at any point throughout the course of these diseases. Some of the early signs of
autoimmune diseases manifested first in the eye, including dry eye disease,
episcleritis, scleritis, uveitis, and retinitis; therefore, optometrist may be the first
clinician in the process of a systemic diagnosis. PUK, however, is a late and most
destructive ocular manifestation of these systemic diseases.1 We present a case
report of PUK in a patient with a history of rheumatoid arthritis and other
comorbidities including chronic obstructive lung disease and deep vein thrombosis.
The patient passed away within five months of the initial ocular manifestations.
CASE REPORT

A 76-year-old Caucasian male presented with a history red eye OD that started 2
weeks ago. He saw an outside optometrist and was treated with erythromycin
ointment for one week. The redness persisted with worsening ocular pain so he
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went to an urgent care clinic for further evaluation. He was then referred to our eye
clinic. His medical history consisted of multiple systemic problems including
chronic obstructive lung disease, hyperlipidemia, deep vein thrombosis, diabetes,
hypothyroidism, and rheumatoid arthritis. His active medication list included
Symbicort, tiotropium, atorvastatin, aspirin, levothyroxine, hydroxychloroquine
and leflunomide. His last comprehensive eye exam two months ago was
unremarkable.
The patient complained of moderate ocular pain and was severely photophobic at
initial presentation. Habitual visual acuity (VA) was 20/80 OD and 20/40-2 OS.
His refractive error was -1.75-2.75x170 OD, -1.50-1.50x157 OS, and ADD+2.50.
His pupils were equal and reactive to light without afferent pupillary defect.
Extraocular movement was full without restriction albeit moderate pain OD.
Confrontation field was full to finger counting. Cover test was orthophoric. Slit
lamp evaluation showed severe conjunctival injection and chemosis, a superior
nasal circular infiltrate and an inferior temporal linear infiltrate across the cornea
with moderate corneal edema (Fig. 1).

Figure 1: Anterior segment photo showed moderate scleritis, superior nasal circular infiltrate,
inferior nasal linear infiltrate with corneal thinning OD at initial visit.
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Goldmann applanation tonometry revealed an intraocular pressure of 14 mmHg
OU. Under the consultation of an ophthalmologist, the patient was diagnosed with
PUK and moderate scleritis associated with RA and was initially treated with
Tobradex (tobramycin-dexamethasone) qid OD. Chart review confirmed the
patient has been treated for RA with hydroxychloroquine and leflunomide for
several years. His rheumatologist was contacted for co-management, and the
patient was to return to clinic in two days.
The patient felt better with Tobradex qid OD over the weekend, but his right eye
still was viscous and sticky in the morning. His VA remained at 20/80 without
improvement. The superior nasal circular infiltrate resolved, and the inferior
temporal linear infiltrate across the cornea and scleritis were resolving, however
peripheral corneal thinning persisted. After consultation with his rheumatologist,
he was put on a pulse treatment of 60 mg prednisone p.o. daily with substitution of
Tobradex qid for ofloxacin qid, and artificial tears qid. After two days of oral
prednisone, the patient felt the same with little improvement, his eye was not sticky
in the morning and the VA improved to 20/50+2 with less conjunctival injection,
corneal edema and linear infiltrate. He was recommended to continue the course of
treatment.
After a week of oral prednisone, his BCVA improved to 20/40-1, corneal infiltrate
resolved but the peripheral cornea was thin, so he was referred to a corneal
specialist for further management while continuing to take prednisone and
ofloxacin. After a month of oral prednisone and awaiting for a corneal specialist
consult, the patient felt that his eyes were not experiencing any pain or discomfort
and doing quite well. His VA was stable at 20/40 OD and the eye has mild
hyperemia nasally with the persistent linear peripheral corneal thinning (Fig. 2).

Figure 2: Anterior segment photo showed resolving scleritis, resolved superior nasal
circular infiltrate and inferior nasal linear infiltrate, but linear corneal thinning persist
OD after one month of treatment.
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Oral prednisone was tapered to 40 mg/d until the next visit in three weeks. At that
visit, he saw his rheumatologist two days prior and was scheduled to see the corneal
specialist in two months. His rheumatologist took him off of leflunomide because
he recently had pneumonia. He continued to take hydroxychloroquine 400 mg/d
and prednisone 40 mg/d. He developed leg edema and elevated blood sugar over
the past several weeks while taking high dose of prednisone. His internist was
informed as a part of the co-management team. His eye felt better and habitual VA
improved to 20/30-2 OD. Anterior segment optical coherence tomography (OCT)
of the cornea confirmed persistent peripheral thinning (Fig. 3).

Figure 3: Anterior segment OCT confirmed paracentral corneal thinning to 500um OD.

Patient was to taper prednisone to 30 mg/d for 2 weeks, then 20 mg/d for 2 weeks
and return to clinic in a month for follow up with dilated fundus exam to monitor
for hydroxychloroquine maculopathy. Unfortunately, the patient passed away from
respiratory complications associated with autoimmune disease before he could
attend his appointment with the corneal specialist.
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DISCUSSION

Peripheral ulcerative keratitis is a manifestation of excessive corneal
inflammatory reaction that leads to corneal tissue damage and subsequent
curvilinear peripheral stromal thinning. It is often associated autoimmune diseases,
with RA being the most common underlying cause. The incidence of PUK is
estimated to be approximately 3 cases per million per year with equal prevalence
in males and females.1 A recent retrospective review of 18 patients with PUK from
a multidisciplinary Uveitis Unit from 1996 to 2017 in Barcelona, Spain identified
8 patients with RA, 2 ANCA-vasculitis, 1 SLE and 1 Takayasu’s arteritis. Three
cases were idiopathic and the other three were infectious. The median age was 72
(range 33-85) and women accounted for majority of the cases. Half of the patients
had associated scleritis and four (33%) patients suffered ocular perforation and
required surgery.2 This study supports the previous findings that RA accounted 3442% of patients with PUK, followed by GPA and SLE.3
Patients usually present with ocular irritation, pain, redness, photophobia, and
impaired vision. Important ocular manifestations include scleritis (especially,
necrotizing scleritis), episcleritis, keratoconjunctivitis sicca, and anterior uveitis.
The differential diagnosis for PUK is broad as it includes other inflammatory
condition such as Mooren’s ulcer, Terrien’s marginal degeneration, Pellucid
marginal degeneration, and other infectious or neoplastic causes.1 Mooren’s ulcer
also presents with painful peripheral corneal thinning, but adjacent scleritis is not
seen. Terrien’s marginal degeneration differs from PUK in that it is a painless,
noninflammatory disease causing peripheral corneal thinning without ulceration.
Pellucid marginal degeneration causes inferior corneal thinning without
inflammation and pain.1 A blood work up is essential in identifying the probable
systemic cause of PUK. Fortunately, the patient was in an integrative health care
system at a VAMC, his blood work up as well as active medical problems were
updated regularly and readily available. For clinicians in other settings, laboratory
tests for potential autoimmune diseases may need to be ordered (Table 2) because
PUK is unlikely to be idiopathic. Furthermore, 50% of PUK cases are associated
with collagen vascular disease.1
Table 2

Laboratory test
Complete Blood Count (CBC)
Complete Metabolic Profile (CMP)
Urinalysis with microscopic analysis
(UA & micro)
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Laboratory test

Indications

Erythrocyte Sedimentation Rate (Sed
Rate)
C-Reactive Protein (CRP)
Antinuclear Antibody (ANA)
Anti-Neutrophil Cytoplasmic Antibody
(ANCA)
Rheumatoid Factor (RF)

Inflammation

Anti-Cyclic Citrullinated Peptide (antiCCP)
Fluorescent Treponemal Antibody
(FTA-Abs)
Purified Protein Derivative (PPD)
Corneal Culture
Ultrasound of the eye

Inflammation
Systemic lupus erythematosus
Granulomatosis with polyangiitis
Rheumatoid arthritis, Sjorgren’s
syndrome
Rheumatoid arthritis
Syphillis
Tuberculosis
Infection
Neoplasm

Table 2: Recommended laboratory test to identify potential systemic cause of PUK.1

The pathogeneses of PUK associated with RA are not fully understood but
cumulative evidence suggests that both T cells and antibodies are involved in the
manifestation.4 Peripheral cornea is well vascularized with abundant immune cells
that can be activated abnormally in RA and other autoimmune diseases. The
deposition of antigen-antibody complexes and subsequent inflammatory reactions
induces macrophages and keratocytes to elevate the levels of proteolytic enzymes
such as matrix metalloproteinases and collagenases that degrade corneal collagens
and extracellular matrices leading to thinning and potential perforation.5
The goal in the treatment of RA is to control synovitis and prevent joint injury.
All patients with active RA are treated with disease-modifying antirheumatic drugs
(DMARDs) to prevent, arrest, or retard joint injury. Methotrexate (MTX),
hydroxycholorquine (HCQ), sulfasalazine (SSZ) and leflunomide (LEF) are the
conventional DMARDs often used as initial therapy with a preference for MTX.
Nonsteroidal anti-inflammatory drugs (NSAIDs, 3200 mg of ibuprofen, 1000 mg
naproxen, or 20 mg piroxicam per day) and/or glucocorticoids (5 to 10 mg/d) is
added for initial symptomatic control of inflammation while awaiting the response
to DMARD therapy.6 Biologic DMARDs including etanercept, adalimumab,
tofacitinib are alternative medications for patients who are unable or unwilling to
take traditional DMARDs. For refractory cases that are not responsive to above
treatments, infliximab or rituximab may be needed.1 The management of acute
PUK is to calm the inflammation by using topical corticosteroid with an adjunct
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broad-spectrum antibiotic to prevent infection because the cornea is compromised.
Systemic corticosteroids are considered first-line therapy to control systemic
inflammation. Topical cyclosporine-A can be considered because it can suppress
damaging immunological response.7 Anterior segment OCT can be used to monitor
for progressive or resolving cornea thinning. When corneal perforation occurs,
surgical procedures involving corneal glue, conjunctival flaps, amniotic membrane
grafts and penetrating keratoplasty are necessary.8
Prior to the advent of efficacious DMARDs, the mortality rate of patients with
RA-associated PUK was up to 50% because it may herald systemic vasculitis.9
After the advent of DMARDs, the mortality rate of patients with RA-associated
PUK is expected to be lower but there has not been a more recent study with
updated estimates. Visual acuity is usually poor for patients with PUK, up to 2/3 of
eyes with corneal melt (with or without perforation) had vision worse than 20/200.10
CONCLUSION

In conclusion, early diagnosis and proper management of PUK in patients with
autoimmune diseases including RA is vital to preserving sight and saving life. A
co-management team consisting of internist, rheumatologist, pharmacist and eye
care providers including corneal specialists are crucial to manage the complexity
of this disease and the adverse side effects posed by systemic therapies.
REFERENCES
1. Artifoni M, Rothschild PR, Brézin A, Guillevin L, Puechal X. Ocular
inflammatory diseases associated with rheumatoid arthritis. Nat Rev
Rheumatol. 2014;10(2):108–116. doi: 10.1038/nrrheum.2013.185
2. Pelegrin L, Hernández-Rodríguez J, Torras J, Espinosa G, Adan A, Sainz MT.
AB0678 Peripheral ulcerative keratitis associated to autoimmune systemic
diseases: visual prognosis and occurrence while systemic disease in remission.
Ann Rheum Dis. 2018;77:1482-1483. doi: 10.1136/annrheumdis-2018eular.4334
3. Levitt AE, McManus KT, McClellan AL, Davis JL, Goldhardt R, Galor A.
Ocular inflammation in the setting of concomitant systemic autoimmune
conditions in an older male population. Cornea. 2015;34(7):762–767. doi:
10.1097/ICO.0000000000000437

Published by The Athenaeum, 2020

Optometric Clinical Practice, Vol. 2 [2020], Iss. 1, Art. 4

4. Maseda D, Bonami RH, Crofford LJ. Regulation of B lymphocytes and plasma
cells by innate immune mechanisms and stromal cells in rheumatoid arthritis.
Exp
Rev
Clin
Immunol.
2014;10(6):747–762.
doi:
10.1586/1744666X.2014.907744
5. Galor A,Thorne JE. Scleritis and peripheral ulcerative keratitis. Rheum Dis Clin
North Am. 2007;33:835–54. doi: 10.1016/j.rdc.2007.08.002
6. Singh JA, Saag KG, Bridges SL Jr, et al. American College of Rheumatology
guideline for the treatment of rheumatoid arthritis. Arthritis Care Res
(Hoboken). 2016;68(1):1-25. doi: 10.1002/acr.22783
7. Kaçmaz RO, Kempen JH, Newcomb C, et al. Cyclosporine for ocular
inflammatory
diseases.
Ophthalmology.
2010;117(3):576–84.
doi: 10.1016/j.ophtha.2009.08.010
8. Jhanji V, Young AL, Mehta JS, Sharma N, Agarwal T, Vajpayee RB.
Management of corneal perforation. Surv Ophthalmol. 2011;56(6):522–538.
doi: 10.1016/j.survophthal.2011.06.003
9. Foster CS, Forstot SL, Wilson LA. Mortality rate in rheumatoid arthritis
patients developing necrotizing scleritis or peripheral ulcerative keratitis.
Effects of systemic immunosuppression. Ophthalmology. 1984;91(10):12531263. doi: 10.1016/s0161-6420(84)34160-4
10. Saripalli L, Harrington TM, Notz RG, Toretti D. Corneal melt in rheumatic
disorders: Effect of disease-modifying antirheumatic drugs on morbidity. J Clin
Rheumatol. 2005;11(3):134–139. doi: 10.1097/01.rhu.0000164819.23298.53

https://athenaeum.uiw.edu/optometric_clinical_practice/vol2/iss1/4
DOI: 10.37685/uiwlibraries.2575-7717.2.1.1016

